Shi and colleagues managed to develop an exosome platform entitled synthetic multivalent antibodies retargeted exosome (SMART-Exo) to provide dual antibodies against CD3 (T-cells) and human epidermal growth factor receptor 2 (HER2) or EGFR in breast cancer [107]. Here, ERBB2 is linked to breast cancer.